Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of January 2023, specifically dated January 13, 2023. The filing details a significant capital raise event involving a Registered Direct Offering and a concurrent Private Placement (PIPE) to secure funding for the Company's operations.
Key Financial Metrics and Capital Structure
The filing focuses on the terms of a securities offering rather than historical operating results. Key financial terms include:
- Expected Gross Proceeds: Approximately $7.5 million (assuming full exercise of Pre-funded Warrants and no exercise of other Warrants), before deducting fees and expenses.
- Offering Price: $5.50 per Ordinary Share (ADS) and associated warrants; $5.499 per Pre-funded Warrant.
- Transaction Costs: A 7% cash placement fee, a 1% management fee, a $75,000 non-accountable expense allowance, and $15,950 in clearing fees payable to H.C. Wainwright & Co., LLC.
- Warrant Terms: Series A Warrants have an exercise price of $6.00 per ADS (5.5-year term); Series B Warrants have an exercise price of $5.50 per ADS (20-month term).
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Transaction Details
The primary material change is the execution of the "Offerings" on January 11, 2023, with an expected closing on or about January 13, 2023. The transaction structure includes:
- Registered Direct Offering: Sale of 90,000,000 Ordinary Shares (300,000 ADSs) and Pre-funded Warrants for 210,000,000 Ordinary Shares (700,000 ADSs), plus unregistered warrants for 600,000,000 Ordinary Shares (2,000,000 ADSs).
- PIPE Offering: Sale of up to 363,637 Pre-funded Warrants (109,091,100 Ordinary Shares) and warrants for 218,182,200 Ordinary Shares.
- Warrant Amendment: Existing warrants issued in December 2021 to the investor were amended, reducing the exercise price from $20.00 to $5.50 per ADS.
- Placement Agent Warrants: H.C. Wainwright & Co., LLC received warrants for 28,636,500 Ordinary Shares at an exercise price of $6.875 per ADS.
Outlook, Risks, and Contingencies
Management commentary is limited to the mechanics of the offering and standard forward-looking statement disclaimers.
- Closing Contingencies: The transaction is expected to close on or about January 13, 2023, subject to customary closing conditions. Failure to satisfy these conditions may prevent the offering from closing.
- Registration Rights: The Company must file a resale registration statement within 20 days of signing and have it declared effective within 60 to 90 days. Failure to do so triggers liquidated damages.
- Restrictions: The Company agreed to a one-year restriction on "variable rate transactions" and a 60-day standstill period following the effective date of the Registration Statement.
- Forward-Looking Risks: The filing explicitly states that forward-looking statements are not guaranteed and may not occur due to reasons beyond the Company's control.
Investor Verification Checklist
- Confirm the actual closing date of the Offerings and whether the expected $7.5 million in gross proceeds was realized.
- Verify the filing and effectiveness status of the resale registration statement required under the Registration Rights Agreement.
- Review the impact of the 7% placement fee and other transaction costs on the net cash received by the Company.
- Assess the dilution impact of the 90 million shares, 210 million pre-funded warrants, and 818 million total warrants issued in this transaction.
- Check for any subsequent filings regarding the exercise of the amended December 2021 warrants.